After Reaching Milestone, Is BIOCARDIA INCORPORATED (OTCMKTS:BCDA)’s Short Interest Revealing Something?

December 8, 2017 - By Marguerite Chambers

The stock of BIOCARDIA INCORPORATED (OTCMKTS:BCDA) registered a decrease of 90.83% in short interest. BCDA’s total short interest was 2,100 shares in December as published by FINRA. Its down 90.83% from 22,900 shares, reported previously.

The stock decreased 0.28% or $0.01 during the last trading session, reaching $3.55. About shares traded. BioCardia, Inc. (OTCMKTS:BCDA) has 0.00% since December 8, 2016 and is . It has underperformed by 16.70% the S&P500.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. The company has market cap of $135.68 million. The Company’s lead therapeutic candidate is the CardiAMP Cell Therapy System that is in Phase III pivotal trials for ischemic systolic heart failure. It currently has negative earnings. The CardiAMP Cell Therapy System comprises cell potency screening test, a point of care cell processing platform, and a biotherapeutic delivery system.

More notable recent BioCardia, Inc. (OTCMKTS:BCDA) news were published by: Businesswire.com which released: “BioCardia Closes Merger With Tiger X Medical, Inc.” on October 24, 2016, also Businesswire.com with their article: “BioCardia, Inc. Reports Third Quarter 2017 Financial Results and Business …” published on November 10, 2017, Businesswire.com published: “BioCardia Completes Roll-in Cohort in Pivotal Phase III CardiAMP Heart Failure …” on July 26, 2017. More interesting news about BioCardia, Inc. (OTCMKTS:BCDA) were released by: Businesswire.com and their article: “BioCardia, Inc. Signs Merger Agreement with Tiger X Medical, Inc., Secures …” published on August 23, 2016 as well as Businesswire.com‘s news article titled: “BioCardia Announces Revised Effective Date of One-for-Twelve Reverse Stock Split” with publication date: November 02, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.